MedPath

Effects of antithyroid drug therapy on bone mineral density of young women with endogenous subclinical hyperthyroidism

Phase 2
Conditions
Subclinical hyperthyroidism.
Thyrotoxicosis, unspecified Hyperthyroidism NOS
Registration Number
IRCT138809012750N1
Lead Sponsor
Kurdistan university of medical sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
30
Inclusion Criteria

Young women referred to Kurdistan nuclear medicine center for thyroid evaluation which has suppressed TSH and normal FT4 and FT3 without history of thyroid disorders.
Exclusion criteria: Secondary osteoporosis, hypersensitivity to oral anti-thyroid drugs, discontinuation of 1 year follow-up

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Thyroid function. Timepoint: 3-6-12 months after treatment. Method of measurement: TSH, freeT3, freeT4 measurement by IRMA & RIA methods.
Secondary Outcome Measures
NameTimeMethod
Bone mineral density. Timepoint: 12 months after treatment or follow-up. Method of measurement: Measuring BMD of lumbar vertebrae(L2-L4) and femoral neck by DXA method.
© Copyright 2025. All Rights Reserved by MedPath